نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - tiaprofenic acid 200mg - tablet - 200 mg - active: tiaprofenic acid 200mg

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - tiaprofenic acid 300mg - tablet - 300 mg - active: tiaprofenic acid 300mg

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - alimemazine tartrate 0.6%{relative};  ; alimemazine tartrate 0.6%{relative} - syrup - 30 mg/5ml - active: alimemazine tartrate 0.6%{relative}   excipient: ascorbic acid citric acid as monohydrate ethanol prunus armeniaca purified water sodium benzoate sodium citrate dihydrate sodium metabisulfite sodium sulfite sucrose active: alimemazine tartrate 0.6%{relative} excipient: ascorbic acid citric acid monohydrate ethanol prunus armeniaca purified water sodium benzoate sodium citrate dihydrate sodium metabisulfite sodium sulfite sucrose - · urticaria

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]);  ; influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]);  ; influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]);   - solution for injection - 10µg/15µg/15µg per dose - active: influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)])   influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)])   influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)])   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin sodium chloride water for injection

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b );  ; influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275);  ; influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 );   - solution for injection - 0.5 ml - active: influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b )   influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275)   influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 )   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin potassium chloride sodium chloride water for injection - vaxigrip is indicated for the prevention of influenza caused by influenza virus types a and b in adults and children aged 6 months and over.

إسرائيل - الإنجليزية - Ministry of Health

sanofi israel ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 100 mg/ml ml - enoxaparin - enoxaparin - clexane is indicated in adults for: • prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

إسرائيل - الإنجليزية - Ministry of Health

sanofi israel ltd - iron as iron iii sodium ferric glugonate compl. - solution for injection/ concentrate for solution for infusion - iron as iron iii sodium ferric glugonate compl. 62.5 mg / 5 ml - various combinations - various combinations - ferrlecit is indicated in adults and children 6 years and above.severe iron deficiency states only when oral administration has been found impossible; in cases of gastrointestinal malabsorption which rules out oral iron therapy; patients treated by dialysis getting erythropoietin.

إسرائيل - الإنجليزية - Ministry of Health

sanofi - aventis israel ltd - adenosine - solution for injection - adenosine 6 mg / 2 ml - adenosine - adenosine - rapid conversion to a normal sinus rhythm of paroxysmal supraventicular tachycardias including those associated with accessory bypass tracts (wolf parkinson-white syndrome).

إسرائيل - الإنجليزية - Ministry of Health

sanofi israel ltd - hydrochlorothiazide; ramipril - tablets - ramipril 2.5 mg; hydrochlorothiazide 12.5 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension.tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone or hydrochlorothiazide alone.

إسرائيل - الإنجليزية - Ministry of Health

sanofi israel ltd - hydrochlorothiazide; ramipril - tablets - ramipril 5 mg; hydrochlorothiazide 25 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension.tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone or hydrochlorothiazide alone.